UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13G
                                 (Rule 13d-102)

 Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)
         and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2(b)

                    Under the Securities Exchange Act of 1934
                               (Amendment No. )*

                                   Amgen Inc.
                                (Name of Issuer)

                   Common Stock, par value $0.0001 per share
                         (Title of Class of Securities)

                                   031162100
                                 (CUSIP Number)

                                 July 15, 2002
             (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


SCHEDULE 13G
CUSIP No.  031162100

1

Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person:

Wyeth

2
Check the Appropriate Box if a Member of a Group        (a)  [  ]
                                                        (b)  [  ]

3
SEC Use Only

4
Citizenship or Place of Organization

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5
Sole Voting Power

        0

6
Shared Voting Power

        98,286,358

7
Sole Dispositive Power

        0

8
Shared Dispositive Power

        98,286,358
9
Aggregate Amount Beneficially Owned by Each Reporting Person

        98,286,358
10
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

[  ]

11
Percent of Class Represented by Amount in Row (9)

        7.7%
12
Type of Reporting Person (See Instructions)

        CO


SCHEDULE 13G
CUSIP No.  031162100

1

Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person:

MDP Holdings, Inc. ("MDP")

2
Check the Appropriate Box if a Member of a Group        (a)  [  ]
                                                        (b)  [  ]

3
SEC Use Only

4
Citizenship or Place of Organization

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5
Sole Voting Power

        0

6
Shared Voting Power

        98,286,358

7
Sole Dispositive Power

        0

8
Shared Dispositive Power

        98,286,358

9
Aggregate Amount Beneficially Owned by Each Reporting Person

        98,286,358

10
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

[  ]

11
Percent of Class Represented by Amount in Row (9)

        7.7%
12
Type of Reporting Person (See Instructions)

        CO

SCHEDULE 13G
CUSIP No.  031162100

Item 1(a).      Name of Issuer:

Amgen Inc. ("Amgen")

Item 1(b).      Address of Issuer's Principal Executive Offices:

One Amgen Center Drive
Thousand Oaks, California 91320-1799

Item 2(a).      Name of Persons Filing:

Wyeth
MDP Holdings, Inc.

Item 2(b).      Address of Principal Business Office or, if None, Residence:

5 Giralda Farms
Madison, New Jersey 07940

Item 2(c).      Citizenship:

Wyeth - Delaware

MDP Holdings, Inc. - Delaware

Item 2(d).      Title of Class of Securities:

Common Stock, par value $0.0001 per share ("Common Stock")

Item 2(e).      CUSIP Number:

031162100

Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or
(c), Check Whether the Person Filing is a:

(a) [  ] Broker or dealer registered under Section 15 of the Exchange Act;

(b) [  ] Bank as defined in section 3(a)(6) of the Exchange Act;

(c) [  ] Insurance company as defined in Section 3(a)(19) of the Exchange Act;

(d) [  ] Investment company registered under Section 8 of the Investment
Company Act;

(e) [  ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) [  ] An employee benefit plan or endowment fund in accordance with Rule
13d-1(b)(1)(ii)(F);

(g) [  ] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);

(h) [  ] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act;

(i) [  ] A church plan that is excluded from the definition of an investment
company under Section 3(c)(14) of the Investment Company Act;

(j) [  ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J);

If this statement is filed pursuant to Rule
13d-1(c), check this box. [ X ]

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage
of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:

Wyeth beneficially owns the 98,286,358 shares of Common Stock held by MDP,
its wholly owned subsidiary. MDP holds directly, and shares voting and
dispositive power with Wyeth with respect to the 98,286,358 shares of Common
Stock.

(b) Percent of Class: 7.7%

The "Percent of Class" and percentages set forth on the cover pages
to this Statement on Schedule 13G were calculated based on 1,038,989,468
outstanding shares of Common Stock as of March 31, 2002, as disclosed in Amgen's
Quarterly Report on Form 10-Q for the quarter ended March 31, 2002 (filed with
the Securities and Exchange Commission (the "SEC") on April 29, 2002), plus
242,300,000 shares of Common Stock, which represents the approximate number of
shares of Common Stock Amgen disclosed, in Amendment No. 1 to its Registration
Statement on Form S-4 filed with the SEC on March 22, 2002 (the "Registration
Statement"), that it anticipated issuing in connection with its merger
transaction with Immunex Corporation ("Immunex"), which was completed on July
15, 2002. As disclosed in the Registration Statement, holders of Immunex common
stock received $4.50 in cash and 0.44 shares of Common Stock per share of
Immunex common stock in the merger.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote                    0

(ii) Shared power to vote or to direct the vote                 98,286,358

(iii) Sole power to dispose or to direct the disposition of     0

(iv) Shared power to dispose or to direct the disposition of    98,286,358

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security
Being Reported on by the Parent Holding Company.

Not applicable.

Item 8.
Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of
the securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.

                                   SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

                                         WYETH

                                         By: /s/ Jack M. O'Connor
                                         Name: Jack M. O'Connor
                                         Title: Vice President and Treasurer



                                         MDP HOLDINGS, INC.

                                         By: /s/ Jeffrey S. Sherman
                                         Name: Jeffrey S. Sherman
                                         Title: Vice President





July 15, 2002

                                    EXHIBITS

Exhibit A - Joint Filing Agreement



                             JOINT FILING AGREEMENT

        We, the signatories of this Statement on Schedule 13G to which this
Agreement is attached, hereby agree that such Statement is, and any amendments
thereto filed by any of us will be, filed in behalf of each of us.


                                         WYETH

                                         By: /s/ Jack M. O'Connor
                                         Name: Jack M. O'Connor
                                         Title: Vice President and Treasurer



                                         MDP HOLDINGS, INC.

                                         By: /s/ Jeffrey S. Sherman
                                         Name: Jeffrey S. Sherman
                                         Title: Vice President


July 15, 2002